Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.77M | 18.58M | 18.36M | 18.85M | 18.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 172.50M | 139.77M | 108.54M | 105.34M | 90.89M |
| Operating Income | -172.50M | -139.77M | -108.54M | -105.34M | -90.89M |
| Income Before Tax | -165.67M | -132.00M | -99.79M | -95.23M | -80.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -165.67 | -132.00 | -99.79 | -95.23 | -80.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.67M | -132.00M | -99.79M | -95.23M | -80.60M |
| EBIT | -172.50M | -139.77M | -108.54M | -105.34M | -90.89M |
| EBITDA | -172.15M | -139.43M | -108.21M | -105.02M | -90.57M |
| EPS Basic | -2.21 | -1.93 | -1.56 | -1.49 | -1.31 |
| Normalized Basic EPS | -1.38 | -1.20 | -0.98 | -0.93 | -0.82 |
| EPS Diluted | -2.21 | -1.93 | -1.56 | -1.49 | -1.31 |
| Normalized Diluted EPS | -1.38 | -1.20 | -0.98 | -0.93 | -0.82 |
| Average Basic Shares Outstanding | 291.50M | 270.13M | 255.61M | 255.38M | 244.97M |
| Average Diluted Shares Outstanding | 291.50M | 270.13M | 255.61M | 255.38M | 244.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |